Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZ5Y1P)

Drug Name
Dichloroacetate Drug Info
Synonyms
2,2-dichloroacetate; Dichloracetate; Dichloroacetate ion; 13425-80-4; Dichloroacetic acid ion(1-); DCA; BRN 3903873; 2q8h; ACETIC ACID, DICHLORO-, ION(1-); 2,2-bis(chloranyl)ethanoate; GTPL4518; CHEBI:28240; DTXSID40158610; STL483470; NCGC00241105-01; 68626-EP2292227A2; 68626-EP2292628A2; 68626-EP2298776A1; 68626-EP2308861A1; 68626-EP2374454A1; A839686; Q27077050
Indication
Disease Entry ICD 11 Status REF
Insulin-resistant disorder 5A44 Phase 4 [1]
Pyruvate dehydrogenase complex deficiency 5C53.02 Phase 3 [2]
Pulmonary fibrosis CB03.4 Phase 1 [3]
Cross-matching ID
PubChem CID
25975
ChEBI ID
CHEBI:28240
CAS Number
CAS 13425-80-4
TTD Drug ID
DMZ5Y1P

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Pyruvate dehydrogenase kinase 1 (PDHK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Heteroaryl-carboxamide derivative 4 DMHUIXR Metastatic cancer 2D50-2E2Z Patented [5]
Pyrazole derivative 61 DMO6M1Q Metastatic cancer 2D50-2E2Z Patented [5]
PMID25684022-Compound-WO2011137219 37(4-6) DMSQ5J8 Metastatic cancer 2D50-2E2Z Patented [5]
Heteroaryl-carboxamide derivative 3 DMBGTNM Metastatic cancer 2D50-2E2Z Patented [5]
Pyrimidine derivative 3 DMC3E8M Metastatic cancer 2D50-2E2Z Patented [5]
Heterocyclic derivative 15 DMWZNDO Metastatic cancer 2D50-2E2Z Patented [5]
Thieno[3,2-c]pyridine-7-carboxamide derivative 2 DMOWFA5 Metastatic cancer 2D50-2E2Z Patented [5]
Heteroaryl-carboxamide derivative 9 DMI627Z Metastatic cancer 2D50-2E2Z Patented [5]
Thiazole carboxamide derivative 24 DMZ6YB0 Metastatic cancer 2D50-2E2Z Patented [5]
Heterocyclic derivative 12 DMQJW9R Metastatic cancer 2D50-2E2Z Patented [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Pyruvate dehydrogenase kinase 1 (PDHK1) TTCZOF2 PDK1_HUMAN Inhibitor [4]

References

1 ClinicalTrials.gov (NCT02469337) Role of Preoperative Carbohydrates Drinks, Dichloroacetate and Exercise on Postoperative Muscle Insulin Resistance (CARBEX). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT02616484) Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency: (DCA/PDCD). U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT01083524) Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension. U.S. National Institutes of Health.
4 Comparison of Antitumor Effects of Combined and Separate Treatment with NO Synthase Inhibitor T1023 and PDK1 Inhibitor Dichloroacetate. Bull Exp Biol Med. 2019 Nov;168(1):92-94.
5 PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37.